CMRAF passionately supports research that will impact the community and lead to healthy living, physically, mentally and emotionally and will provide education to families to better prepare them to combat the onset of addiction.
An article produced in 2019 by Science Advances, states that Opioid use disorders (OUDs) are diseases of the brain with behavioral, psychological, neurobiological, and medical manifestations. Vulnerability to OUDs can be affected by factors such as genetic background, environment, stress, and prolonged exposure to u-opioid agonists for analgesia. Two standard-of-care maintenance medications, methadone and buprenorphine-naloxone, have long-term positive influence on health of persons with opioid addiction. Buprenorphine and another medication, naltrexone, have also been approved for administration as monthly depot injections. However, neither medication is used as widely as needed, due largely to stigma, insufficient medical education or training, inadequate resources, and inadequate access to treatment.
Ongoing directions in the field include:
(i) personalized approaches leveraging genetic factors for prediction of OUD vulnerability and prognosis, or for targeted pharmacotherapy,
(ii) development of novel analgesic medicines with new neurobiological targets with reduced abuse potential, reduced toxicity, and improved effectiveness, especially for chronic pain states other than cancer pain
Copyright © CMRAF.ORG
Proin lacinia, est lobortis iaculis pulvinar, sapien erat rhoncus nisi, sed elementum risus urna non quam. Sed eu erat vulputate, euismod sem a, tristique sapien. Aliquam sagittis iaculis diam, vitae hendrerit lorem vulputate eleifend